Cho et al [42] reported that Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies, while overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. This evidence concerns the gene ERBB2 and neoplasm.